H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Viridian Therapeutics to $40 from $35 and keeps a Buy rating on the shares. The company provided a reminder of the upcoming milestones it expects to achieve, which could offer room for upside in shares from current levels, the analyst tells investors in a research note. The firm says Viridian’s programs for the treatment of thyroid eye disease keep progressing.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VRDN:
- Viridian Therapeutics reports Q4 EPS ($1.13), consensus (73c)
- Viridian Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates
- Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Viridian Therapeutics to participate in a conference call with JMP Securities
- Viridian Appoints Scott Myers as President and Chief Executive Officer
